MX2013012281A - Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias. - Google Patents

Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.

Info

Publication number
MX2013012281A
MX2013012281A MX2013012281A MX2013012281A MX2013012281A MX 2013012281 A MX2013012281 A MX 2013012281A MX 2013012281 A MX2013012281 A MX 2013012281A MX 2013012281 A MX2013012281 A MX 2013012281A MX 2013012281 A MX2013012281 A MX 2013012281A
Authority
MX
Mexico
Prior art keywords
treatment
degenerative
diseases
inflammatory diseases
novel compound
Prior art date
Application number
MX2013012281A
Other languages
English (en)
Other versions
MX355653B (es
Inventor
Christel Jeanne Marie Menet
Alastair James Hodges
Huw David Vater
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2013012281A publication Critical patent/MX2013012281A/es
Publication of MX355653B publication Critical patent/MX355653B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan pirrazolopiridinas novedosas de acuerdo con la fórmula I, capaces de inhibir JAK, estos compuestos se pueden preparar como una composición farmacéutica y pueden ser utilizados para la profilaxis y tratamiento de una diversidad de condiciones en mamíferos incluyendo humanos, que incluyen, a modo de ejemplo no limitante, alergias, condiciones inflamatorias, enfermedades autoinmunes, enfermedades proliferativas, rechazo de transplantes, enfermedades que involucran deterioro de recambio del cartílago, malformaciones congénitas del cartílago y/o enfermedades asociadas con hipersecreción de IL6 o interferones.
MX2013012281A 2011-04-28 2012-04-26 Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias. MX355653B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161479956P 2011-04-28 2011-04-28
PCT/EP2012/057654 WO2012146659A1 (en) 2011-04-28 2012-04-26 Novel compound useful for the treatment of degenerative and inflammatory diseases

Publications (2)

Publication Number Publication Date
MX2013012281A true MX2013012281A (es) 2013-11-21
MX355653B MX355653B (es) 2018-04-26

Family

ID=46017860

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013012282A MX360697B (es) 2011-04-28 2012-04-26 Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias.
MX2013012281A MX355653B (es) 2011-04-28 2012-04-26 Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013012282A MX360697B (es) 2011-04-28 2012-04-26 Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias.

Country Status (18)

Country Link
US (5) US8975406B2 (es)
EP (2) EP2702058B1 (es)
JP (2) JP5947371B2 (es)
KR (1) KR101934707B1 (es)
CN (2) CN103492385B (es)
AR (1) AR086042A1 (es)
AU (2) AU2012247484B2 (es)
BR (1) BR112013027338A2 (es)
CA (2) CA2833942A1 (es)
EA (1) EA024743B1 (es)
HK (2) HK1195312A1 (es)
IL (1) IL228786A (es)
MX (2) MX360697B (es)
SG (1) SG194508A1 (es)
TW (1) TWI536990B (es)
UY (1) UY34037A (es)
WO (2) WO2012146659A1 (es)
ZA (1) ZA201307793B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
CN105338965A (zh) * 2013-04-29 2016-02-17 赛诺菲股份有限公司 可吸入药用组合物和含有该药用组合物的吸入器装置
GB201321733D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
KR101690760B1 (ko) * 2014-11-05 2016-12-30 조길래 피부자극완화, 탈모방지 및 발모촉진 효과를 나타내는 카페오일펜타펩타이드 및 이를 함유하는 탈모방지 및 발모촉진용 화장료 조성물
TW201705961A (zh) * 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
US10919875B2 (en) 2015-06-18 2021-02-16 89Bio Ltd Substituted 4-benzyl and 4-benzoyl piperidine derivatives
CA3014554A1 (en) 2015-06-18 2016-12-22 Cephalon, Inc. 1,4-substituted piperidine derivative for treating a disorder mediated by fatty acid synthase
PL3322706T3 (pl) 2015-07-16 2021-07-19 Array Biopharma, Inc. Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
DE102015215820A1 (de) * 2015-08-19 2017-02-23 Siemens Healthcare Gmbh Steuern eines medizintechnischen Geräts
WO2018019223A1 (zh) * 2016-07-26 2018-02-01 张文燕 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途
JOP20190077A1 (ar) * 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018163971A1 (ja) * 2017-03-09 2018-09-13 富士フイルム株式会社 音響レンズ用樹脂材料、音響レンズ、音響波プローブ、音響波測定装置、超音波診断装置、光音響波測定装置および超音波内視鏡
EA037208B1 (ru) * 2017-09-29 2021-02-19 Эррей Биофарма Инк. ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EA035568B1 (ru) * 2017-09-29 2020-07-08 Эррей Биофарма Инк. ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
TW202410896A (zh) 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI783057B (zh) 2017-10-10 2022-11-11 美商絡速藥業公司 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
EP3845531A4 (en) * 2018-09-30 2021-11-24 Applied Pharmaceutical Science, Inc. SUBSTITUTED PYRAZOLE-CONDENSED RING DERIVATIVES, METHOD FOR THEIR PRODUCTION AND USE THEREOF
KR20210100155A (ko) * 2018-12-07 2021-08-13 선샤인 레이크 파르마 컴퍼니 리미티드 Ret 억제제, 이의 약학 조성물 및 용도
CA3117854A1 (en) * 2018-12-07 2020-06-11 Sunshine Lake Pharma Co., Ltd. Ret inhibitors, pharmaceutical compositions and uses thereof
US20230159523A1 (en) * 2020-04-22 2023-05-25 Shenzhen Zhongge Biological Technology Co., Ltd. Pyrazolo[1,5-a]pyridine derivative, preparation method therefor, and composition and use thereof
CN113713083A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种用于治疗脱发的药物组合
US20230348496A1 (en) 2020-09-01 2023-11-02 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
KR20230104143A (ko) 2020-09-28 2023-07-07 주식회사 퍼스트바이오테라퓨틱스 조혈 전구 키나아제 1(hpk1) 억제제로서의 인다졸 및 이의 사용 방법
EP4284801A1 (en) * 2021-02-01 2023-12-06 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
US20240174662A1 (en) * 2021-02-01 2024-05-30 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
EP4384523A1 (en) 2021-08-10 2024-06-19 Syngenta Crop Protection AG 2,2-difluoro-5h-[1,3]dioxolo[4,5-f]isoindol-7-one derivatives as pesticides
CN114409675B (zh) * 2022-01-07 2023-08-04 重庆医科大学 螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途
WO2023187191A1 (en) 2022-04-01 2023-10-05 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2024156664A1 (en) 2023-01-23 2024-08-02 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503712A (ja) 2004-06-21 2008-02-07 ガラパゴス・ナムローゼ・フェンノートシャップ 骨関節炎治療の方法及び手段
AU2007291190A1 (en) * 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2727036C (en) * 2008-06-20 2017-03-21 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica

Also Published As

Publication number Publication date
ZA201307793B (en) 2015-04-29
JP2014512405A (ja) 2014-05-22
EP2702058B1 (en) 2015-08-19
IL228786A0 (en) 2013-12-31
US20160213666A1 (en) 2016-07-28
CA2833963C (en) 2019-09-17
CN103492385A (zh) 2014-01-01
JP5947372B2 (ja) 2016-07-06
UY34037A (es) 2012-11-30
CN103492385B (zh) 2016-05-11
US20140051677A1 (en) 2014-02-20
CA2833942A1 (en) 2012-11-01
US8975406B2 (en) 2015-03-10
AU2012247482B2 (en) 2015-03-05
AR086042A1 (es) 2013-11-13
MX2013012282A (es) 2013-11-21
US9241931B2 (en) 2016-01-26
US20120277247A1 (en) 2012-11-01
AU2012247484B2 (en) 2015-02-19
TWI536990B (zh) 2016-06-11
KR20140025430A (ko) 2014-03-04
CN103492386A (zh) 2014-01-01
MX355653B (es) 2018-04-26
JP5947371B2 (ja) 2016-07-06
AU2012247484A1 (en) 2013-03-28
EA024743B1 (ru) 2016-10-31
BR112013027338A2 (pt) 2017-08-08
US20150031706A1 (en) 2015-01-29
HK1195312A1 (zh) 2014-11-07
IL228786A (en) 2017-04-30
EP2702058A1 (en) 2014-03-05
US9987272B2 (en) 2018-06-05
US8802682B2 (en) 2014-08-12
MX360697B (es) 2018-11-14
SG194508A1 (en) 2013-12-30
WO2012146657A1 (en) 2012-11-01
EP2702059A1 (en) 2014-03-05
WO2012146659A1 (en) 2012-11-01
NZ617528A (en) 2015-09-25
CA2833963A1 (en) 2012-11-01
AU2012247482A1 (en) 2013-03-28
JP2014512404A (ja) 2014-05-22
EP2702059B1 (en) 2015-08-19
EA201391584A1 (ru) 2014-04-30
TW201247202A (en) 2012-12-01
HK1195311A1 (zh) 2014-11-07
KR101934707B1 (ko) 2019-01-03
CN103492386B (zh) 2016-03-09
US20180078547A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
MX355653B (es) Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.
JO3030B1 (ar) مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
PH12014502615B1 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
NZ722403A (en) Pharmaceutical compositions for the treatment of inflammatory disorders
GB2483424A (en) 5-Phenyl-[1,2,4] triazolo[1,5-A] pyridin-2-yl carboxamides as JAK inhibitors
TW201613873A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2014002442A (es) Inhibidores de pirrolopirazina cinasa.
MX2016010068A (es) Sales novedosas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios.
NZ702334A (en) New diazaspirocycloalkane and azaspirocycloalkane
GB2489382A (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
PH12020550230A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AR089960A1 (es) Compuesto de imidazolopiridina para el tratamiento de enfermedades degenerativas e inflamatorias
MX2012002385A (es) Inhibidores macrociclicos de cinasa janus.
PH12019501853A1 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX337610B (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
UA105796C2 (uk) Сполука, застосовна для лікування дегенеративних і запальних захворювань
MX350565B (es) Composiciones farmaceuticas.

Legal Events

Date Code Title Description
FG Grant or registration